Paper Details

  1. Home
  2. Paper Details

Are All Biologics the Same? Optimal Treatment Strategies for Patients With Early Rheumatoid Arthritis: Systematic Review and Indirect Pairwise Meta-Analysis.

Author: AlbertDaniel A

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

A meta-analysis of six randomized controlled trials found that biologic agents in conjunction with a DMARD performed similarly in DMARD-naive RA patients. However, etanercept 50 mg appeared superior to adalimumab 40 mg, golimumab 50 mg, and infliximab 3 and 6 mg/kg at ACR20. Rituximab 1000 mg and etanercept 50 mg appeared superior to golimumab 100 mg at ACR50.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The use of biologic agents has revolutionized the treatment of rheumatoid arthritis (RA). However, there is much uncertainty about whether any agent may be preferable. PURPOSE: The aim of the study was to evaluate the comparative efficacy of biologic agents with a disease-modifying anti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/RHU.0000000000000272

データ提供：米国国立医学図書館（NLM）

Navigating the Landscape of Biologics for Rheumatoid Arthritis

This comprehensive study dives into the world of rheumatoid arthritis (RA), exploring the efficacy of various biologic agents in treating this debilitating autoimmune disease. The researchers conducted a systematic review and meta-analysis of randomized controlled trials, comparing the effectiveness of different biologics in conjunction with a disease-modifying antirheumatic drug (DMARD) in patients without prior exposure to a DMARD.

The Power of Biologics: A Promising Therapeutic Frontier

The meta-analysis revealed that all six biologic therapies examined were significantly more effective than DMARD alone in achieving a clinically meaningful improvement in RA symptoms, as measured by the American College of Rheumatology (ACR) response rates. However, the study also found some subtle differences between the biologics, suggesting that certain agents may be more effective for specific patient subgroups.

Implications for Personalized Treatment and Future Research

This research emphasizes the need for personalized treatment approaches in RA, considering the specific characteristics of each patient. It also highlights the importance of conducting head-to-head clinical trials to directly compare the efficacy and safety of different biologic agents, allowing clinicians to make more informed treatment decisions.

Dr.Camel's Conclusion

Just as a desert oasis can offer a variety of resources, so too can the realm of biologic therapies offer a diverse range of options for treating RA. This study provides valuable insights into the effectiveness of these agents, emphasizing the need for personalized treatment approaches and further research to optimize patient outcomes.
Date :
  1. Date Completed 2016-09-02
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

26226612

DOI: Digital Object Identifier

10.1097/RHU.0000000000000272

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.